Researchers at Daewoong Pharmaceutical are conducting research to develop next-generation drug delivery technologies. Provided by Daewoong Pharmaceutical.
Daewoong Pharmaceutical announced on the 9th that it will embark on the development of next-generation drug delivery technologies in the form of high-concentration subcutaneous injections and skin patches.
Daewoong Pharmaceutical has signed separate joint drug development agreements using the high-concentration subcutaneous injection platform “Thermicra” and the dissolvable microneedle platform “CLOPAM,” both developed by Daewoong Therapeutics. Thermicra will be co-developed by Daewoong Pharmaceutical, Daewoong Therapeutics, and Daewoong Bio, while CLOPAM will be jointly developed by Daewoong Pharmaceutical and Daewoong Therapeutics.
Thermicra is a technology designed to convert antibody drugs and antibody-drug conjugates (ADCs), which have conventionally been administered via intravenous (IV) injection, into subcutaneous (SC) formulations. According to the company, it can achieve high-concentration formulations of 400 mg/mL or more without the use of hyaluronidase enzymes that promote subcutaneous dispersion of drugs.
It is designed to suppress the increase in viscosity that occurs in high-concentration formulations and to reduce the risk of protein denaturation. Through this, the company plans to pursue the development of drugs that can shorten administration time and simplify procedures compared with intravenous injections.
CLOPAM is a patch-type platform that delivers drugs as the micro-needles inserted into the skin dissolve. Using a precision dispensing process, it uniformly controls the amount of drug loaded into each micro-needle, and employs pressurized drying technology to concentrate the drug at the tips of the micro-needles. Daewoong Pharmaceutical is reviewing its applicability to small-molecule compounds, peptide drugs, and other modalities.
The company is also pushing ahead with the construction of manufacturing facilities. For Thermicra, it plans to build a dedicated manufacturing site in Seongnam, Gyeonggi Province, with completion scheduled for December 2027. For CLOPAM, a dedicated aseptic clinical drug manufacturing facility is being built at Daewoong Bio’s Plant 3 in Hyangnam, Hwaseong, Gyeonggi Province, with the goal of obtaining Good Manufacturing Practice (GMP) approval in the first half of 2027.
Daewoong Pharmaceutical plans to apply the two platforms to multiple drugs rather than limiting them to specific products, thereby expanding its pipeline of development candidates.
Park Sung-soo, CEO of Daewoong Pharmaceutical, said, “This joint development will serve as a stepping stone to apply next-generation drug delivery technologies to various drugs and lead to product launches,” adding, “We will expand our product portfolio through collaboration among the three companies.”
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News